Morning Overview on MSN
A targeted pill and a custom mRNA vaccine are both beating back pancreatic cancer in early trials — cracking open one of medicine’s hardest tumors
Pancreatic ductal adenocarcinoma has a five-year survival rate of roughly 13 percent, according to the American Cancer ...
Morning Overview on MSN
Two new pancreatic cancer treatments — a targeted pill and a personalized mRNA vaccine — are beating back one of medicine’s deadliest tumors in early trials
Pancreatic cancer has long been oncology’s most stubborn adversary. Fewer than 13% of patients survive five years after ...
Scientists found that leaking mitochondrial RNA helps pancreatic tumors survive, revealing a promising new treatment target.
In an unexpected finding, a new study flips on its head researchers' understanding of how precancerous pancreas lesions ...
New clinical trial data show KRAS-blocking drugs may significantly improve survival for the disease. “I think this is truly ...
Pancreatitis is a complex inflammatory disease driven by both genetic and environmental factors. It poses substantial ...
A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients ...
Metabolic dysfunction–associated steatotic liver disease (MASLD) is associated with increased rates of acute non-biliary pancreatitis, chronic pancreatitis, and pancreatic cancer, contributing to a ...
Salmonid alphaviruses are single-stranded RNA viruses responsible for pancreas disease (PD), a condition characterised by exocrine pancreatic necrosis, cardiac inflammation and skeletal muscle damage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results